Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK Cells and Azacitidine for MDS-EB
NCT04599426Phase 2Unknown
- Sponsor
- Second Hospital of Shandong University
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of AlloNK in myelodysplastic syndrome (MDS), sponsored by Second Hospital of Shandong University. Status: unknown.
02
Drugs
AlloNK
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04599426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04599426.